STENOCARE is sharing early information about the upcoming share issue “TO2 Warrant” transaction in June 2024
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“Stenocare”) announced a year ago (May 2023) that the company would raise capital through three different share issue transactions. The last of these transactions is the upcoming “TO2 Warrant” transaction, starting on June 10, 2024. Important: Only owners of TO2 Warrants will be able to subscribe (buy) new Stenocare shares at a 30% discount during the transaction window from June 10-21.
Stenocare like to highlight the following points about the TO2 Warrant transaction:
- Owning TO2 Warrants is a requirement for subscribing to the new Stenocare shares with a discount of 30%.
- Shareholders that subscribed for the Stenocare UNIT Right Issue during May/June 2023 also received TO2 Warrants that can now be exercised (used) or sold to the market.
- Becoming an owner of TO2 Warrants: TO2 Warrants are being traded daily and can be purchased or sold under ticker “STENO TO 2” or using the ISIN code DK0062493615.
- Each TO2 Warrant owned, entitles the owner subscribe (buy) one new Stenocare share with a discount of 30%.
- The discount arises as the subscription price for the new shares is calculated as subtracting a 30% discount of the 10-day volume weighted average price of the Stenocare mother share as traded on Nasdaq First North Growth Market Denmark in the period May 27 to June 7. The price will be announced on June 7, 2024 (after 17:00 Central European Time).
- TO2 Warrants that are NOT sold or used to subscribe for new shares with a discount before June 21 (time 17:00 CET) will become void.
Stenocare is advising current owners of TO2 Warrants to actively decide how to use their warrants. Start by checking the actual number of TO2 Warrants owned in your account. There are four different options:
- Use all the TO2 Warrants to subscribe for new Stenocare shares at a 30% discount during June 10-21.
- Use all the TO2 Warrants and purchase additional TO2 Warrants to subscribe for more Stenocare shares at a discount.
- Use only part of the TO2 Warrants for new Stenocare shares at a discount and sell the remaining TO2 Warrants before June 19, 2024.
- Decide not to use the TO2 Warrants and sell all TO2 Warrants before June 19, 2024.
Information about the upcoming TO2 Warrant is available on the investor homepage: https://stenocare.com/to2-warrant-introduction/
Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.